Dublin, July 05, 2019 (GLOBE NEWSWIRE) -- The "Capmatinib" report has been added to ResearchAndMarkets.com's offering.

Capmatinib (Incyte/Novartis) is an orally bioavailable inhibitor of the proto-oncogene c-MET, also called hepatocyte growth factor receptor (HGFR).

C-MET is a receptor tyrosine kinase, and abnormal activation in cancer can trigger tumor growth, angiogenesis, and metastasis. As a result, patients with aberrant c-MET activity typically have poor prognosis, aggressive disease, and shortened survival. Capmatinib selectively binds to c-MET, thereby disrupting c-MET signaling pathways. This can induce cell death in tumor cells with high c-MET amplification.

Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Capmatinib: Non-small cell lung cancer (NSCLC)

List of Figures
Figure 1: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Figure 2: Imfinzi for non-small cell lung cancer - SWOT analysis
Figure 3: Tagrisso sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26
Figure 4: The authors drug assessment summary for Tecentriq in non-small cell lung cancer

List of Tables
Table 1: Capmatinib drug profile
Table 2: Capmatinib pivotal in non-small cell lung cancer
Table 3: Capmatinib early-phase data in non-small cell lung cancer
Table 4: Gilotrif sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Capmatinib patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/f71xpu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.